Lilly to showcase diversity of Alzheimer’s disease pipeline at AAIC® 2016

pharmafield logo - pharma news

Eli Lilly and Company is to present findings from more than 25 research studies at the upcoming Alzheimer’s Association International Conference® 2016 (AAIC® 2016) in Toronto, Canada.

The data highlight a broad research programme that targets beta-amyloid and tau proteins, two known hallmarks of Alzheimer’s disease, along with positron emission tomography (PET) imaging diagnostics that allow researchers to estimate both pathologies in the living brain.

Dr J. Anthony Ware, senior vice president, product development, Lilly Bio-Medicine, said: “Our current pipeline is shaped by the discoveries we’ve made over nearly three decades of research and development. We recognise the significant burden this devastating illness has on patients, caregivers and our society, and we remain deeply committed to finding ways to disrupt the course of this disease.”

Of interest are two oral presentations which may inform Lilly’s future clinical research in Alzheimer’s disease:

  • The Relationship of PET Tau Images to Changes in Cognition over Time 
  • Evolution of PET Tau Signal: Interim Analysis of an 18-Month Phase 2 Study.
Additional studies being presented include:

  • Solanezumab data
  • Florbetapir data
  • Flortaucipir data
  • AZD3293/LY3314814 data (BACE Inhibitor)
  • LY3202626 data (BACE Inhibitor)
  • LY2811376 data (BACE Inhibitor)
  • m266 Fab data
  • General Alzheimer’s disease data.
  • AAIC® 2016 will run from July 24 to 28.